Discovery and Identification of Novel 5‑Hydroxy‑4H‑benzo[1,4]oxazin-3-one Derivatives as Potent β2‑Adrenoceptor Agonists through Structure-Based Design, Synthesis, and Biological Evaluation

• Published in: Journal of medicinal chemistry Vol. 67; no. 4; pp. 2986 - 3003
• Main Authors: Xing, Gang, Li, Zhenli, Zhi, Zhengxing, Yi, Ce, Zhang, Ruiwen, Yang, Huali, Zhang, Yuyang, Lin, Bin, Liu, Yang, Pan, Li, Cheng, Maosheng
• Format: Journal Article
• Language: English
• Published: WASHINGTON American Chemical Society 22.02.2024; Amer Chemical Soc
• Subjects: Chemistry, Medicinal; Life Sciences & Biomedicine; Pharmacology & Pharmacy; Science & Technology
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/acs.jmedchem.3c02074

Although β2-agonists are crucial for treatment of chronic respiratory diseases, optimizing β2-agonistic activity and selectivity remains essential for achieving favorable therapeutic outcomes. A structure-based molecular design workflow was employed to discover a novel class of β2 agonists featuring a 5-hydroxy-4H-benzo­[1,4]­oxazin-3-one scaffold, which potently stimulated β2 adrenoceptors (β2-ARs). Screening for the β2-agonistic activity and selectivity led to the identification of compound A19 (EC50 = 3.7 pM), which functioned as a partial β2-agonist in HEK-293 cells containing endogenous β2-ARs. Compound A19 exhibited significant relaxant effects, rapid onset time (Ot50 = 2.14 min), and long duration of action (>12 h) on isolated guinea pig tracheal strips, as well as advantageous pharmacokinetic characteristics in vivo, rendering A19 suitable for inhalation administration. Moreover, A19 suppressed the upregulation of inflammatory cytokines and leukocytes and improved lung function in a rat model of COPD, thereby indicating that A19 is a potential β2 agonist candidate for further study.